Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

10.0%

4 terminated out of 40 trials

Success Rate

78.9%

-7.6% vs benchmark

Late-Stage Pipeline

10%

4 trials in Phase 3/4

Results Transparency

47%

7 of 15 completed with results

Key Signals

7 with results79% success

Data Visualizations

Phase Distribution

36Total
Not Applicable (19)
Early P 1 (1)
P 1 (1)
P 2 (11)
P 3 (3)
P 4 (1)

Trial Status

Completed15
Recruiting10
Unknown8
Terminated4
Withdrawn1
Active Not Recruiting1

Trial Success Rate

78.9%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (40)

Showing 20 of 20 trials
NCT07211438Phase 2RecruitingPrimary

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression

NCT05779267UnknownPrimary

NRX-101 Expanded Access

NCT06341426Phase 2Active Not Recruiting

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin

NCT04996433Not ApplicableRecruiting

A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients

NCT05710237Phase 2CompletedPrimary

Does Psilocybin Require Psychedelic Effects to Treat Depression?

NCT05842291Not ApplicableSuspendedPrimary

pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression

NCT03653858Not ApplicableCompletedPrimary

Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression

NCT07274917Not ApplicableRecruitingPrimary

Stereotactic Radiotherapy Treatment for Treatment-resistant Depression

NCT04680910Phase 1CompletedPrimary

Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I

NCT07166289Not ApplicableRecruitingPrimary

Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression

NCT05377177Not ApplicableRecruiting

Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI

NCT05045378Phase 4CompletedPrimary

Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression

NCT07094789Not ApplicableRecruitingPrimary

Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression

NCT07108257Not ApplicableRecruitingPrimary

Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression

NCT05661383Not ApplicableRecruitingPrimary

Olfactory and Brain Stimulations in Treatment-resistant Depression

NCT04821271Phase 2Terminated

Antidepressant Effects of TS-161 in Treatment-Resistant Depression

NCT05800860Phase 2CompletedPrimary

A Trial of GH001 in Patients With Treatment-resistant Depression

NCT06372834Not ApplicableCompleted

Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients

NCT06404320Not ApplicableRecruitingPrimary

Physical Activity Program for TRD

NCT02497287Phase 3CompletedPrimary

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

Scroll to load more

Research Network

Activity Timeline